152 related articles for article (PubMed ID: 27084489)
1. An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing.
Bienk K; Hvam ML; Pakula MM; Dagnæs-Hansen F; Wengel J; Malle BM; Kragh-Hansen U; Cameron J; Bukrinski JT; Howard KA
J Control Release; 2016 Jun; 232():143-51. PubMed ID: 27084489
[TBL] [Abstract][Full Text] [Related]
2. Enhanced extravasation, stability and in vivo cardiac gene silencing via in situ siRNA-albumin conjugation.
Lau S; Graham B; Cao N; Boyd BJ; Pouton CW; White PJ
Mol Pharm; 2012 Jan; 9(1):71-80. PubMed ID: 22141328
[TBL] [Abstract][Full Text] [Related]
3. Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing.
Sarett SM; Werfel TA; Lee L; Jackson MA; Kilchrist KV; Brantley-Sieders D; Duvall CL
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6490-E6497. PubMed ID: 28739942
[TBL] [Abstract][Full Text] [Related]
4. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
[TBL] [Abstract][Full Text] [Related]
5. Systemic delivery of stable siRNA-encapsulating lipid vesicles: optimization, biodistribution, and tumor suppression.
Dar GH; Gopal V; Rao NM
Mol Pharm; 2015 Feb; 12(2):610-20. PubMed ID: 25545110
[TBL] [Abstract][Full Text] [Related]
6. Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors.
Son S; Song S; Lee SJ; Min S; Kim SA; Yhee JY; Huh MS; Chan Kwon I; Jeong SY; Byun Y; Kim SH; Kim K
Biomaterials; 2013 Dec; 34(37):9475-85. PubMed ID: 24050874
[TBL] [Abstract][Full Text] [Related]
7. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo.
Wong SC; Klein JJ; Hamilton HL; Chu Q; Frey CL; Trubetskoy VS; Hegge J; Wakefield D; Rozema DB; Lewis DL
Nucleic Acid Ther; 2012 Dec; 22(6):380-90. PubMed ID: 23181701
[TBL] [Abstract][Full Text] [Related]
8. Trimeric Small Interfering RNAs and Their Cholesterol-Containing Conjugates Exhibit Improved Accumulation in Tumors, but Dramatically Reduced Silencing Activity.
Chernikov IV; Gladkikh DV; Karelina UA; Meschaninova MI; Ven'yaminova AG; Vlassov VV; Chernolovskaya EL
Molecules; 2020 Apr; 25(8):. PubMed ID: 32325757
[TBL] [Abstract][Full Text] [Related]
9. Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration.
Glud SZ; Bramsen JB; Dagnaes-Hansen F; Wengel J; Howard KA; Nyengaard JR; Kjems J
Oligonucleotides; 2009 Jun; 19(2):163-8. PubMed ID: 19441893
[TBL] [Abstract][Full Text] [Related]
10. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
Chen S; Tam YY; Lin PJ; Leung AK; Tam YK; Cullis PR
J Control Release; 2014 Dec; 196():106-12. PubMed ID: 25285610
[TBL] [Abstract][Full Text] [Related]
11. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo.
Judge AD; Bola G; Lee AC; MacLachlan I
Mol Ther; 2006 Mar; 13(3):494-505. PubMed ID: 16343994
[TBL] [Abstract][Full Text] [Related]
12. Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis.
Jiang G; Park K; Kim J; Kim KS; Hahn SK
Mol Pharm; 2009; 6(3):727-37. PubMed ID: 19178144
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo.
Mook OR; Baas F; de Wissel MB; Fluiter K
Mol Cancer Ther; 2007 Mar; 6(3):833-43. PubMed ID: 17363479
[TBL] [Abstract][Full Text] [Related]
14. Cell-penetrating cationic siRNA and lipophilic derivatives efficient at nanomolar concentrations in the presence of serum and albumin.
Perche P; Nothisen M; Bagilet J; Behr JP; Kotera M; Remy JS
J Control Release; 2013 Aug; 170(1):92-8. PubMed ID: 23639452
[TBL] [Abstract][Full Text] [Related]
15. Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system.
McCarthy J; O'Neill MJ; Bourre L; Walsh D; Quinlan A; Hurley G; Ogier J; Shanahan F; Melgar S; Darcy R; O'Driscoll CM
J Control Release; 2013 May; 168(1):28-34. PubMed ID: 23500058
[TBL] [Abstract][Full Text] [Related]
16. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice.
Sato A; Takagi M; Shimamoto A; Kawakami S; Hashida M
Biomaterials; 2007 Mar; 28(7):1434-42. PubMed ID: 17141864
[TBL] [Abstract][Full Text] [Related]
17. Histological Quantification of Gene Silencing by Intratracheal Administration of Dry Powdered Small-Interfering RNA/Chitosan Complexes in the Murine Lung.
Ihara D; Hattori N; Horimasu Y; Masuda T; Nakashima T; Senoo T; Iwamoto H; Fujitaka K; Okamoto H; Kohno N
Pharm Res; 2015 Dec; 32(12):3877-85. PubMed ID: 26138669
[TBL] [Abstract][Full Text] [Related]
18. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing.
Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC
J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968
[TBL] [Abstract][Full Text] [Related]
19. Tumor Selective Silencing Using an RNAi-Conjugated Polymeric Nanopharmaceutical.
Svenson S; Case RI; Cole RO; Hwang J; Kabir SR; Lazarus D; Lim Soo P; Ng PS; Peters C; Shum P; Sweryda-Krawiec B; Tripathi S; van der Poll D; Eliasof S
Mol Pharm; 2016 Mar; 13(3):737-47. PubMed ID: 26835715
[TBL] [Abstract][Full Text] [Related]
20. Gene silencing efficiency of siRNA-PEG conjugates: effect of PEGylation site and PEG molecular weight.
Jung S; Lee SH; Mok H; Chung HJ; Park TG
J Control Release; 2010 Jun; 144(3):306-13. PubMed ID: 20206653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
